Palisade Bio
PALI
5 hedge funds and large institutions have $19M invested in Palisade Bio in 2015 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 4 closing their positions.
45% more call options, than puts
Call options by funds: $551K | Put options by funds: $380K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
44% less funds holding
Funds holding: 9 → 5 (-4)
47% less capital invested
Capital invested by funds: $35.6M → $19M (-$16.6M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 4
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$1.84M |
| 2 |
Goldman Sachs
New York
|
-$1.84M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$1.84M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.84M |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$337K |
PALI Hedge Fund Activity: Q3 2015 in Review
5 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2015, worth a combined $19M — down 47% from $35.6M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of PALI and 0 opened new positions — a net loss of 4 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Credit Suisse, exiting entirely with an estimated $1.84M sold.
- 5 institutional investors held Palisade Bio (PALI) as of Q3 2015, down from 9 in Q2 2015.
- Funds reported $19M of Palisade Bio stock for Q3 2015, down 47% quarter-over-quarter.
- 0 funds opened new Palisade Bio positions in Q3 2015 and 4 closed out, a net change of -4 holders.
- The largest Palisade Bio seller in Q3 2015 was Credit Suisse, an estimated $1.84M sold.
Based on aggregated 13F filings for Q3 2015.